Creative Planning’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31M Buy
40,152
+10,018
+33% +$7.67M 0.02% 305
2025
Q4
$23.3M Buy
30,134
+10,195
+51% +$6.92M 0.02% 330
2025
Q3
$11.2M Buy
19,939
+10,454
+110% +$5.91M 0.01% 524
2025
Q2
$4.98M Sell
9,485
-1,882
-17% -$1.05M ﹤0.01% 760
2025
Q1
$7.21M Buy
11,367
+1,209
+12% +$832K 0.01% 590
2024
Q4
$7.24M Sell
10,158
-1,635
-14% -$1.37M 0.01% 549
2024
Q3
$12.4M Buy
11,793
+2,178
+23% +$2.42M 0.01% 382
2024
Q2
$10.1M Buy
9,615
+991
+11% +$961K 0.01% 405
2024
Q1
$8.3M Buy
8,624
+1,535
+22% +$1.46M 0.01% 459
2023
Q4
$6.23M Buy
7,089
+421
+6% +$347K 0.01% 512
2023
Q3
$5.49M Buy
6,668
+551
+9% +$433K 0.01% 501
2023
Q2
$4.4M Buy
6,117
+350
+6% +$270K 0.01% 555
2023
Q1
$4.74M Buy
5,767
+645
+13% +$486K 0.01% 523
2022
Q4
$3.7M Buy
5,122
+731
+17% +$539K 0.01% 553
2022
Q3
$3.02M Buy
4,391
+467
+12% +$294K 0.01% 562
2022
Q2
$2.32M Buy
3,924
+1,225
+45% +$796K ﹤0.01% 669
2022
Q1
$1.89M Sell
2,699
-25
-0.9% -$15.8K ﹤0.01% 740
2021
Q4
$1.72M Buy
2,724
+270
+11% +$166K ﹤0.01% 735
2021
Q3
$1.49M Sell
2,454
-535
-18% -$332K ﹤0.01% 778
2021
Q2
$1.67M Sell
2,989
-3,317
-53% -$1.68M ﹤0.01% 739
2021
Q1
$2.98M Buy
6,306
+1,401
+29% +$682K 0.01% 560
2020
Q4
$2.37M Buy
4,905
+591
+14% +$319K 0.01% 603
2020
Q3
$2.42M Buy
4,314
+605
+16% +$367K 0.01% 495
2020
Q2
$2.31M Sell
3,709
-433
-10% -$246K 0.01% 453
2020
Q1
$2.02M Sell
4,142
-1,489
-26% -$614K 0.01% 435
2019
Q4
$2.11M Sell
5,631
-6,578
-54% -$2.21M 0.01% 497
2019
Q3
$3.39M Buy
12,209
+201
+2% +$59.5K 0.01% 365
2019
Q2
$3.76M Buy
12,008
+8,529
+245% +$2.84M 0.01% 342
2019
Q1
$1.43M Sell
3,479
-49
-1% -$20.2K 0.01% 589
2018
Q4
$1.32M Sell
3,528
-950
-21% -$348K 0.01% 559
2018
Q3
$1.81M Sell
4,478
-5,917
-57% -$2.25M 0.01% 509
2018
Q2
$3.59M Buy
10,395
+1,238
+14% +$387K 0.01% 332
2018
Q1
$3.15M Sell
9,157
-1,639
-15% -$570K 0.01% 351
2017
Q4
$4.06M Sell
10,796
-5,451
-34% -$2.21M 0.02% 287
2017
Q3
$7.26M Buy
16,247
+2,542
+19% +$1.21M 0.03% 179
2017
Q2
$6.73M Sell
13,705
-4,910
-26% -$2.15M 0.03% 183
2017
Q1
$7.21M Buy
18,615
+2,596
+16% +$962K 0.04% 170
2016
Q4
$5.88M Sell
16,019
-1,741
-10% -$662K 0.04% 189
2016
Q3
$7.14M Buy
17,760
+3,026
+21% +$1.21M 0.05% 159
2016
Q2
$5.15M Buy
14,734
+4,135
+39% +$1.59M 0.04% 167
2016
Q1
$3.82M Buy
10,599
+7,992
+307% +$3.29M 0.03% 190
2015
Q4
$1.42M Sell
2,607
-581
-18% -$315K 0.01% 396
2015
Q3
$1.48M Buy
+3,188
New +$1.71M 0.01% 364
2015
Q2
Sell
-1,989
Closed -$898K 2574
2015
Q1
$898K Sell
1,989
-156
-7% -$66.1K 0.01% 505
2014
Q4
$880K Sell
2,145
-341
-14% -$134K 0.01% 496
2014
Q3
$896K Buy
2,486
+815
+49% +$273K 0.01% 437
2014
Q2
$472K Buy
1,671
+236
+16% +$69.9K 0.01% 665
2014
Q1
$431K Buy
1,435
+110
+8% +$33.9K 0.01% 689
2013
Q4
$365K Sell
1,325
-61
-4% -$17.5K 0.01% 618
2013
Q3
$434K Buy
1,386
+656
+90% +$173K 0.01% 486
2013
Q2
$164K Buy
+730
New +$170K ﹤0.01% 748

Other funds holding REGN

Creative Planning's REGN Position: Q1 2026 in Review

Creative Planning increased its Regeneron Pharmaceuticals (REGN) stake by 33% in Q1 2026, buying an estimated $7.67M and bringing the position to 40,152 shares worth $31M. The position accounts for 0.02% of the portfolio, ranked #305.

Creative Planning first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Creative Planning held 40,152 shares of Regeneron Pharmaceuticals worth $31M as of Q1 2026.
  • Creative Planning bought 10,018 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $7.67M.
  • Regeneron Pharmaceuticals made up 0.02% of Creative Planning's portfolio in Q1 2026, its #305 holding.
  • Creative Planning first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.